Pfizer Inc. (PFE)

43.07
0.19 0.44
NYSE : Health Technology
Prev Close 42.88
Open 42.82
Day Low/High 42.82 / 43.33
52 Wk Low/High 35.87 / 46.47
Volume 21.66M
Avg Volume 21.16M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 238.06B
EPS 1.90
P/E Ratio 22.51
Div & Yield 1.44 (3.27%)
Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Here's what you're missing on TheStreet.

The Market Is 'Full Blown Bear,' Says Jim Cramer

The Market Is 'Full Blown Bear,' Says Jim Cramer

Worried about the market? Jim Cramer has some advice for investors.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer responds to the news that the drug company, Pfizer, has hiked rates.

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Let's check our indicators.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

Carlos Ghosn, Apple, US-China Trade, Bitcoin and Pfizer - 5 Things You Must Know

Carlos Ghosn, Apple, US-China Trade, Bitcoin and Pfizer - 5 Things You Must Know

U.S. stocks futures indicated a firmer open Monday, even as reports suggest Renault CEO Carlos Ghosn faces arrest in Japan after Nissan said he had misused company funds and will be ousted as chairman; Apple is sliding again on fresh iPhone demand reports; U.S.-China trade tensions simmer; Bitcoin falls to a 13-month low and Pfizer plans 2019 durg price hikes.

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

Once Again It Is Breadth That Has My Eye

Breadth continues to outperform for now.

Pfizer Becomes #10 Most Shorted Dow Stock, Replacing Exxon Mobil

Pfizer Becomes #10 Most Shorted Dow Stock, Replacing Exxon Mobil

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's Conservative Pricing Offers Protection From Political Pressure

Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.

What Is the Dow Jones Industrial Average?

What Is the Dow Jones Industrial Average?

The Dow Jones Industrial Average is a price-weighted average of 30 large American publicly traded companies on the stock market.

I Can't Believe I Missed on Altria Stock

I Can't Believe I Missed on Altria Stock

Altria had been one of my staples in the past.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

U.S. FDA Approves LORBRENA® (lorlatinib) For Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) For Previously-Treated ALK-Positive Metastatic NSCLC

Pfizer Inc. (NYSE:PFE) today announced that the U.

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Apple, Microsoft and Some Two-Dozen Other Stocks to Own in November

Stephen 'Sarge' Guilfoyle gives you a rundown of what's in his portfolio as the new month gets rolling.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Jim Cramer: Here's What I Saw That Justified Today's Rally

Jim Cramer: Here's What I Saw That Justified Today's Rally

Some groups that have been in horrendous bear market mode finally caught a bid.

Dow Closes Sharply Higher as Late Surge Pushes Stock Gains

Dow Closes Sharply Higher as Late Surge Pushes Stock Gains

The Dow Jones Industrial Average led major market indexes higher with a late surge Tuesday after closing lower during the previous session for the eighth time in 11 trading days.

Pfizer Tops Q3 Earnings Estimate, Narrows Full-Year Guidance Range

Pfizer Tops Q3 Earnings Estimate, Narrows Full-Year Guidance Range

Pfizer posts stronger-than-expected third-quarter earnings but narrows its guidance range for full-year sales.

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

US Stocks Rebound as Earnings Drive Sentiment Amid Renewed Trade War Concerns

Global stocks attempted yet another rebound Tuesday, with reports of direction market intervention in China supporting prices in Asia and stronger-than-expected blue chip earnings putting European bourses on solid footing following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average and a further worrying plunge in big-name tech companies.

Facebook, General Electric, Apple, BP and IGC - 5 Things You Must Know

Facebook, General Electric, Apple, BP and IGC - 5 Things You Must Know

U.S. stock futures rise modestly on Tuesday following a volatile session on Wall Street that saw a 900-point swing for the Dow Jones Industrial Average; Facebook, GE, Coca-Cola and Pfizer report earnings; Apple is expected to unveil a new iPad and perhaps a new MacBook Air at an event Tuesday.

Will the Bear Win Out? What Earnings Reports to Watch This Week

Will the Bear Win Out? What Earnings Reports to Watch This Week

TheStreet takes a look at the final week of Q3 earnings.

Staying Long Apple Into Tuesday's Product Launch: Market Recon

Staying Long Apple Into Tuesday's Product Launch: Market Recon

My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.

PFIZER REPORTS THIRD-QUARTER 2018 RESULTS

PFIZER REPORTS THIRD-QUARTER 2018 RESULTS

Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2018 and narrowed certain 2018 financial guidance ranges.

Pfizer Announces Clinical Development Agreement With Novartis To Advance The Treatment Of NASH

Pfizer Announces Clinical Development Agreement With Novartis To Advance The Treatment Of NASH

Pfizer Inc. (NYSE:PFE) announced today that it has entered into a non-exclusive clinical development agreement with Novartis (NYSE: NVS) to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH).

TheStreet Quant Rating: B (Buy)